Lytix Biopharma AS (LYTIX) — Financial Flexibility Index
Lytix Biopharma AS (LYTIX) has a Financial Flexibility Index of -3.03x as of December 2025. Free cash flow of Nkr-59.85 Million (operating CF Nkr-59.85 Million minus capex Nkr0.00) represents -3% of total liabilities (Nkr19.77 Million). Check asset allocation strategy of Lytix Biopharma AS to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Lytix Biopharma AS Financial Flexibility Index (2017–2025)
Historical Financial Flexibility Index trend for Lytix Biopharma AS across 9 annual periods. See Lytix Biopharma AS short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Lytix Biopharma AS (2017–2025)
Year-by-year free cash flow to debt coverage for Lytix Biopharma AS. For the full company profile including market capitalisation, see market value of Lytix Biopharma AS.
| Year | Flexibility Index | Free Cash Flow (NOK) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -3.03x | Nkr-59.85 Million | Nkr-59.85 Million | Nkr19.77 Million | ▼ -66.2% |
| 2024 | -1.82x | Nkr-70.37 Million | Nkr-70.37 Million | Nkr38.64 Million | ▲ +76.2% |
| 2023 | -7.64x | Nkr-95.92 Million | Nkr-95.97 Million | Nkr12.55 Million | ▼ -148.4% |
| 2022 | -3.08x | Nkr-51.95 Million | Nkr-52.10 Million | Nkr16.89 Million | ▲ +8.3% |
| 2021 | -3.35x | Nkr-44.74 Million | Nkr-44.90 Million | Nkr13.34 Million | ▼ -76.5% |
| 2020 | -1.90x | Nkr-24.19 Million | Nkr-24.35 Million | Nkr12.73 Million | ▲ +80.0% |
| 2019 | -9.51x | Nkr-36.67 Million | Nkr-36.82 Million | Nkr3.85 Million | ▼ -133.9% |
| 2018 | -4.07x | Nkr-72.62 Million | Nkr-72.62 Million | Nkr17.85 Million | ▼ -106.1% |
| 2017 | -1.97x | Nkr-69.67 Million | Nkr-69.67 Million | Nkr35.30 Million | — |